ECO 2026 12 - 15 May 2026

OASIS 4: Efficacy of Oral Semaglutide 25 mg in Obesity Treatment Targets and Low-risk Outcomes for Cardiometabolic Risk Factors

Authors :

Carel W. Le Roux¹; Oscar Birkhan²; Naveen Rathor²; Domenica Rubino³; Chaithra Shaji⁴; Luca Busetto⁵

Affiliations

View Details Hide Details

Download .PDF

{{ getPageNum(PDFPage) }}

Keywords

Obesity

Congress poster

GLP-1 RA

Semaglutide (oral)

PHASE 3 (RCT)